Remarkable Response of EGFR- and HER2- Amplified Metastatic Colon Cancer to Pyrotinib After Failed Multiline Treatments: A Case Report and Literature Review

Hong-Shuai Li; Li-Li Yang; Ming-Yi Zhang; Ke Cheng; Ye Chen; Ji-Yan Liu

doi:10.3389/fonc.2020.548867

Remarkable Response of EGFR- and HER2- Amplified Metastatic Colon Cancer to Pyrotinib After Failed Multiline Treatments: A Case Report and Literature Review

Front Oncol. 2020 Oct 26:10:548867. doi: 10.3389/fonc.2020.548867. eCollection 2020.

Authors

Hong-Shuai Li^{1

2}, Li-Li Yang³, Ming-Yi Zhang^{1

2}, Ke Cheng⁴, Ye Chen⁴, Ji-Yan Liu^{1

2}

Affiliations

¹ Department of Biotherapy, Cancer Center, and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China.
² Sichuan Clinical Research Center of Biotherapy, Chengdu, China.
³ Department of Medical Oncology, Chengdu Shangjinnanfu Hospital/West China Hospital of Sichuan University, Chengdu, China.
⁴ Department of Abdominal Oncology, West China Hospital of Sichuan University, Chengdu, China.

Abstract

Human epidermal growth factor receptor 2 (HER2) has been verified as a valuable biomarker and treatment target in metastatic colorectal cancer (mCRC). Pyrotinib, a novel irreversible HER2/epidermal growth factor receptor (EGFR) dual tyrosine kinase inhibitor, can efficiently inhibit the proliferation of HER2-positive cancer cells in many tumors. We report a case of a 40-year-old woman with both HER2- and EGFR-amplified metastatic colon cancer, who developed refractory disease resistant to multiline therapies (including trastuzumab with lapatinib) but achieved a remarkable response after pyrotinib treatment. For patients with HER2-positive mCRC, who have developed resistance to trastuzumab and lapatinib, pyrotinib is a promising new candidate, which can be used as salvage therapy.

Keywords: colorectal cancer; human epidermal growth factor receptor 2; pyrotinib; resistance; trastuzumab.

Publication types

Case Reports